July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Glucocorticoid-induced ocular hypertension leads to progressive retinal ganglion cell loss, impaired axonal transport and optic nerve degeneration in mice
Author Affiliations & Notes
  • prabhavathi maddineni
    NTERI, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Ramesh Kasetti
    NTERI, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Pinkal Patel
    NTERI, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Amith Sope
    NTERI, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Gulab Zode
    NTERI, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Footnotes
    Commercial Relationships   prabhavathi maddineni, None; Ramesh Kasetti, None; Pinkal Patel, None; Amith Sope, None; Gulab Zode, None
  • Footnotes
    Support  EY022077
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3704. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      prabhavathi maddineni, Ramesh Kasetti, Pinkal Patel, Amith Sope, Gulab Zode; Glucocorticoid-induced ocular hypertension leads to progressive retinal ganglion cell loss, impaired axonal transport and optic nerve degeneration in mice. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3704.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ocular hypertension (OHT) and secondary iatrogenic open angle glaucoma are the serious side effects of glucocorticoid (GC) therapy, which is used widely to treat various immune mediated diseases. We have previously developed a novel mouse model of GC-induced OHT using weekly periocular injections of potent GC, dexamethasone (Dex). The purpose of this study is to examine whether sustained Dex-induced OHT leads to glaucoma phenotype in mice

Methods : Three-month old C57BL/6J mice (n=30) were injected with either Dex-Acetate (200µg/eye) or vehicle suspension via periocular route, once in a week for 10-weeks. IOP was measured every week and pattern electro retinogram (pERG) was used to measure RGC function at 10-weeks post injections. Alexa Flour 594-cholera toxin B (CTB) was injected intravitreally, to trace the deficits in anterograde axon transport. Abnormal extracellular matrix (ECM) deposition in trabecular meshwork (TM) was assessed by immunostaining. RGC loss was analyzed by whole mount retina staining with RBPMS antibody and axon degeneration was examined by PPD staining.

Results : Weekly injections of Dex but not vehicle caused sustained and pronounced IOP elevation in mice, starting from 1-week of injection (Δ ≥3.5mmHg IOP). In addition, Dex reduced the outflow facility (~30%) and also induced abnormal ECM proteins (fibronectin and collagen I) deposition in TM. pERG revealed significant deficits in RGCs function as evident from reduced pERG amplitudes (10µV v/s 25 µV) with increased N1 latency periods (140ms v/s 100ms) in Dex-injected mice compared to vehicle injected mice. Importantly, we observed a highly significant RGC loss in Dex-mice (loss was ~60% in periphery and ~50% in mid-periphery). Axon anterograde transport tracer CTB accumulated in ONH of Dex-mice, indicating deficits in axonal transport. PPD-stained cross sections of optic nerves showed severe axonal damage in Dex-mice, whereas no damage was observed in vehicle injected mice

Conclusions : These data suggest that our novel mouse model of periocular Dex-induced OHT develops glaucoma phenotype. Also, there are many clinical, morphological, and molecular similarities between our Dex-induced glaucoma model and POAG, making this mice model as an attractive model to study the specific aspects of POAG, including TM and RGCs pathology in glaucoma.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×